Stocks · News reference
Filed: 2026-11-03 AccNo: 0001628280-26-069493 Size: 254 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analysts have updated the 12-month price target for Contineum Therapeutics, Inc. to $21.43, reflecting a potential upside of approximately 121% based on the November 3, 2026, closing price.
Contineum Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2026.
Contineum Therapeutics, Inc. announced that its management team is scheduled to participate in a fireside chat at the Stifel 2026 Healthcare Conference on November 12, 2026.
Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR received a new $60 target.
Baird analyst Joel Beatty downgrades Contineum Therapeutics (NASDAQ:CTNM) from Outperform to Neutral and lowers the price target from $19 to $14.